- Home
- ABSI vs GHRS Comparison
ABSI vs GHRS Comparison
Compare ABSI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- GHRS
- Stock Information
- Founded
- ABSI 2011
- GHRS 2018
- Country
- ABSI United States
- GHRS Ireland
- Employees
- ABSI N/A
- GHRS N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- GHRS Health Care
- Exchange
- ABSI Nasdaq
- GHRS Nasdaq
- Market Cap
- ABSI 338.0M
- GHRS 960.2M
- IPO Year
- ABSI 2021
- GHRS 2021
- Fundamental
- Price
- ABSI $3.10
- GHRS $17.57
- Analyst Decision
- ABSI Strong Buy
- GHRS Strong Buy
- Analyst Count
- ABSI 4
- GHRS 8
- Target Price
- ABSI $8.75
- GHRS $30.63
- AVG Volume (30 Days)
- ABSI 4.9M
- GHRS 185.2K
- Earning Date
- ABSI 08-13-2025
- GHRS 09-02-2025
- Dividend Yield
- ABSI N/A
- GHRS N/A
- EPS Growth
- ABSI N/A
- GHRS N/A
- EPS
- ABSI N/A
- GHRS N/A
- Revenue
- ABSI $4,815,000.00
- GHRS N/A
- Revenue This Year
- ABSI $74.53
- GHRS N/A
- Revenue Next Year
- ABSI $296.01
- GHRS N/A
- P/E Ratio
- ABSI N/A
- GHRS N/A
- Revenue Growth
- ABSI N/A
- GHRS N/A
- 52 Week Low
- ABSI $2.01
- GHRS $6.00
- 52 Week High
- ABSI $6.33
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- ABSI 60.72
- GHRS 71.70
- Support Level
- ABSI $2.55
- GHRS $15.25
- Resistance Level
- ABSI $2.92
- GHRS $16.90
- Average True Range (ATR)
- ABSI 0.15
- GHRS 1.22
- MACD
- ABSI 0.03
- GHRS 0.28
- Stochastic Oscillator
- ABSI 91.23
- GHRS 83.45
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.